Lupin gets USFDA nod to market skin ointment

The product will be manufactured at the company's Pithampur, Unit 3 facility, Lupin said in a filing to the BSE. The approval by the United States Food and Drug Administration (USFDA) is to market its generic Betamethasone Dipropionate ointment USP (augmented), 0.05 per cent, it added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Z6JB13
via IFTTT